Wolters Kluwer new integration tool

A new service from Wolters Kluwer Health integrates several of the marketing research firm's data points into a single source, offering financial analysts and brand managers a new forecasting capability. 
The product, inThought, was developed in order to streamline forecasting capabilities for drugmakers, to help them understand where developmental drugs, medical devices and therapies are positioned in the market, and what sort of splash they could make in the future.


"With research headcounts down, there's a fundamental shift in the way analysts and pharma customers want their research delivered," said Ben Weintraub, director of research, in a statement. "Rather than simply striving to offer more data faster, our approach sifts through the clutter to synthesize what is truly important."


Clients can use the tool for monitoring global drug developments, and tap into forecasts of approval models for over 300 drugs in development.

You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.